Atara Biotherapeutics, Inc. (ATRA) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Atara Biotherapeutics, Inc. (ATRA) Healthcare & Pipeline Overview

Atara Biotherapeutics, Inc. pioneers off-the-shelf T-cell immunotherapies, targeting cancers, autoimmune disorders, and viral diseases. Their lead program, tabelecleucel, addresses Epstein-Barr virus-driven diseases, while their CAR T-cell therapies aim to treat hematologic malignancies and solid tumors, positioning them in the competitive biotechnology landscape.

What Is the Investment Thesis for ATRA?

Atara Biotherapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. A key value driver is the potential FDA approval and commercialization of tabelecleucel for EBV-driven PTLD, with Phase 3 trial results anticipated to drive near-term valuation. The company's CAR T-cell therapy programs, particularly those targeting mesothelin and B-cell malignancies, represent significant long-term growth catalysts. However, Atara faces challenges including clinical trial execution, regulatory hurdles, and competition from established pharmaceutical companies. The company's current market capitalization of $84.5M, coupled with a profit margin of 27.1%, suggests potential upside if clinical programs succeed, but also exposes investors to substantial downside risk if trials fail or regulatory approval is not obtained. Successful execution of clinical trials and strategic partnerships are critical for Atara to realize its potential.

Based on FMP financials and quantitative analysis

ATRA Key Highlights

Market capitalization of $84.5M reflects the company's current valuation in the biotechnology sector.

• Profit margin of 27.1% indicates efficient cost management relative to revenue, although this can fluctuate significantly for biotech companies.
• Gross margin of 82.4% demonstrates strong pricing power for its products and services, assuming consistent revenue generation.
• Beta of -0.40 suggests the stock is less volatile than the overall market, potentially offering some downside protection during market downturns.
• Development of tabelecleucel, a T-cell immunotherapy in Phase 3 clinical trials, represents a near-term catalyst for potential FDA approval and commercialization.

Who Are ATRA's Competitors?

ATRA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ATRA's Key Strengths?

Proprietary off-the-shelf T-cell immunotherapy platform.

• Clinical data supporting the efficacy of tabelecleucel.
• Strategic collaborations with leading research institutions.
• Experienced management team with expertise in immunotherapy development.

What Are ATRA's Weaknesses?

Limited financial resources compared to larger pharmaceutical companies.

• Dependence on the success of tabelecleucel and other pipeline programs.
• High regulatory hurdles and clinical trial risks.
• Relatively small number of employees (153).

What Could Drive ATRA Stock Higher?

Phase 3 clinical trial results for tabelecleucel in EBV-driven post-transplant lymphoproliferative disease (PTLD).

• Clinical data updates from CAR T-cell therapy programs targeting mesothelin and B-cell malignancies.
• Regulatory submissions and potential FDA approval for tabelecleucel.
• Strategic partnerships and collaborations for funding and commercialization.

What Are the Key Risks for ATRA?

Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.

• Clinical trial failures or regulatory setbacks for tabelecleucel and other pipeline programs.
• Competition from established pharmaceutical companies with CAR T-cell therapies.
• Patent challenges or intellectual property infringement.
• Dependence on the success of key pipeline programs.
• Limited financial resources compared to larger pharmaceutical companies.

What Are the Growth Opportunities for ATRA?

• Expansion of Tabelecleucel's Indications: Atara has the opportunity to expand the use of tabelecleucel beyond post-transplant lymphoproliferative disease (PTLD) to other Epstein-Barr virus (EBV)-associated malignancies, such as nasopharyngeal carcinoma (NPC). The market for NPC treatment is estimated to reach $1.8 billion by 2030. Successful clinical trials in these additional indications would significantly increase tabelecleucel's market potential and solidify Atara's position in EBV-related cancer therapies.
• Advancement of CAR T-Cell Therapy Programs: Atara's next-generation CAR T-cell therapies, including ATA2271 and ATA3271 targeting mesothelin for solid tumors, represent a significant growth opportunity. The solid tumor CAR T-cell therapy market is projected to reach $12 billion by 2028. Positive clinical data and strategic partnerships could accelerate the development and commercialization of these programs, establishing Atara as a leader in solid tumor immunotherapy.
• Development of ATA188 for Multiple Sclerosis: ATA188, an immunotherapy for multiple sclerosis (MS), offers a diversification opportunity for Atara beyond oncology. The MS therapeutics market is expected to reach $30 billion by 2027. Successful clinical trials demonstrating efficacy in MS could position ATA188 as a novel treatment option and expand Atara's market reach into autoimmune diseases.
• Strategic Partnerships and Collaborations: Atara can leverage strategic partnerships and collaborations to accelerate the development and commercialization of its therapies. Collaborations with academic institutions, such as Memorial Sloan Kettering Cancer Center and QIMR Berghofer Medical Research Institute, provide access to innovative technologies and expertise. Strategic partnerships with pharmaceutical companies, such as Bayer AG, can provide funding and commercialization support.
• Geographic Expansion: Atara has the opportunity to expand its geographic reach beyond the United States and Europe. The market for cancer immunotherapies is growing rapidly in Asia-Pacific, particularly in countries like China and Japan. Establishing a presence in these markets through strategic partnerships or direct investment could significantly increase Atara's revenue potential.

What Are ATRA's Competitive Advantages?

• Proprietary off-the-shelf T-cell immunotherapy platform.
• Clinical data supporting the efficacy of tabelecleucel in EBV-driven diseases.
• Strategic collaborations with leading research institutions and pharmaceutical companies.
• Intellectual property protection for its T-cell immunotherapy technologies.

What Does ATRA Do?

Atara Biotherapeutics, Inc., founded in 2012 and headquartered in South San Francisco, California, is a biotechnology company focused on developing novel allogeneic or ‘off-the-shelf’ T-cell immunotherapies. These therapies are designed to treat patients suffering from cancer, autoimmune diseases, and viral infections. The company's lead product candidate is tabelecleucel (tab-cel®), an allogeneic T-cell immunotherapy in Phase 3 clinical trials for the treatment of Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease (PTLD), as well as other EBV-associated hematologic and solid tumors, including nasopharyngeal carcinoma (NPC). Beyond tabelecleucel, Atara is developing a pipeline of next-generation CAR T immunotherapies targeting various cancers. These include ATA2271 and ATA3271, which target mesothelin, a protein expressed in several solid tumors; ATA2431 and ATA3219, targeting B-cell malignancies; and ATA188, an immunotherapy for multiple sclerosis (MS). The company is also developing ATA368 for human papillomavirus (HPV)-associated cancers. Atara has established strategic collaborations and license agreements with institutions like Memorial Sloan Kettering Cancer Center, QIMR Berghofer Medical Research Institute, H. Lee Moffitt Cancer Center, and Bayer AG, enhancing its research and development capabilities and expanding its therapeutic pipeline. Atara's innovative approach to off-the-shelf T-cell immunotherapy positions it as a key player in the rapidly evolving field of cancer and autoimmune disease treatment.

What Products and Services Does ATRA Offer?

• Develop off-the-shelf T-cell immunotherapies for cancer, autoimmune, and viral diseases.
• Advance tabelecleucel, a T-cell immunotherapy, through Phase 3 clinical trials for Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease (PTLD).
• Develop next-generation CAR T immunotherapies for hematologic malignancies and solid tumors.
• Target mesothelin with ATA2271 and ATA3271 for solid tumors.
• Develop ATA2431 and ATA3219 for B-cell malignancies.
• Develop ATA188 for the treatment of multiple sclerosis.
• Develop ATA368 program for patients with human papillomavirus associated cancers.
• Establish strategic collaborations with research institutions and pharmaceutical companies.

How Does ATRA Make Money?

• Develop and commercialize off-the-shelf T-cell immunotherapies.
• Generate revenue through product sales upon regulatory approval.
• Establish strategic partnerships and collaborations to fund research and development.
• Out-license or co-develop therapies with pharmaceutical companies for commercialization.

What Industry Does ATRA Operate In?

Atara Biotherapeutics operates within the highly competitive and rapidly evolving biotechnology industry. The market for cancer immunotherapies is projected to reach $79.4 billion by 2027, driven by increasing cancer prevalence and advancements in personalized medicine. Atara's focus on off-the-shelf T-cell therapies differentiates it from companies developing autologous CAR T-cell therapies, which are more expensive and time-consuming to manufacture. Key competitors include companies like Gilead and Novartis, which have established CAR T-cell therapy platforms. Atara's success depends on its ability to navigate regulatory hurdles, demonstrate clinical efficacy, and secure strategic partnerships.

Who Are ATRA's Key Customers?

• Patients with cancer, autoimmune diseases, and viral infections.
• Hospitals and oncology clinics.
• Pharmaceutical companies through licensing and collaboration agreements.
• Research institutions through research collaborations.

Company Profile

Atara Biotherapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO Anhco Nguyen. ATRA has traded publicly since 2014.

Return on equity for Atara Biotherapeutics, Inc. stands at 25.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -47.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -29.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.16 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -6.8%, the inverse of the P/E and a quick read on earnings relative to price.

ATRA Valuation & Market Position

With a $84.5M market cap, Atara Biotherapeutics, Inc. sits in the micro-cap segment of the market. Relative to its peer group, ATRA's quantitative score of 18/100 is below the peer average of 70/100.

Quarterly Financial Performance: Atara Biotherapeutics, Inc.

Revenue for Atara Biotherapeutics, Inc. came in at $630K during Q2 2026, a 22.1% improvement versus the preceding quarter. The company recorded a net loss of $4.8M, with diluted EPS of $-0.32. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, ATRA averaged $-0.29 in diluted EPS.

Atara Biotherapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

Wall Street analysts project Atara Biotherapeutics, Inc. revenue of about $2.1M for fiscal 2026, with EPS near $-1.29.

ATRA Financials

ATRA Latest News

ATRA Analyst Consensus

ATRA MoonshotScore

Common Questions About ATRA (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources